TG101209

Target: This ligand targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings Janus kinase 2 (JAK2) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated BRD4 Degradation: TG101209 can be used as a ligand component in PROTAC constructs to recruit an E3 ligase and drive ubiquitin-dependent degradation of BRD4 in cells. This enables functional interrogation of BRD4 biology by shifting from inhibition to targeted protein removal, supporting studies of transcriptional regulation and chromatin-associated pathways.

• Mechanistic Studies of Ubiquitination: Incorporating TG101209 into PROTAC designs allows researchers to probe how ternary complex formation and ubiquitination kinetics govern degradation efficiency. By comparing degradation versus occupancy and monitoring proteasome dependence, investigators can map rate-limiting steps and optimize linker and E3 engagement strategies for robust BRD4 turnover.

• Cell-Based Target Validation: TG101209-based PROTACs are suitable for validating BRD4 as a causal driver of phenotypes by measuring concentration- and time-dependent loss of BRD4 protein. This approach supports orthogonal confirmation relative to small-molecule inhibitors, helping distinguish effects due to degradation from those arising from transient target binding.

• Optimization of Degrader Potency: TG101209 can serve as a starting ligand for structure-guided PROTAC optimization, including linker length, attachment position, and E3 ligase selection. Systematic variation enables tuning of ternary complex stability and cellular residence time, improving degradation potency, selectivity, and durability of BRD4 depletion for downstream pathway analyses.

TG101209 is a JAK2-oriented ligand scaffold useful for designing kinase-directed PROTAC analogs. Its basic piperazine-containing periphery provides a plausible region for linker-vector exploration.

Structure: TG101209 is a JAK2-oriented aminopyrimidine scaffold bearing two arylamino substituents, a sulfonamide group, a tert-butyl substituent, and an N-methylpiperazine side chain. It combines a heteroaryl hinge-binding region with polar sulfonamide and basic tertiary amine functionality.

Reactivity: TG101209 can guide JAK-targeted PROTAC design, with the N-methylpiperazine or sulfonamide-associated aryl periphery representing more plausible solvent-facing linker vectors than the aminopyrimidine core. Linkers containing alkyl, PEG, amide, sulfonamide-compatible, or tertiary-amine motifs may be paired with CRBN, VHL, or IAP ligands. Since the parent molecule has no dedicated reactive handle, a linker-ready analog is preferred for controlled coupling.